TY - JOUR
T1 - Hepatitis B virus resistance to nucleos(t)ide analogue therapy
T2 - WHO consultation on questions, challenges, and a roadmap for the field
AU - Lumley, Sheila F.
AU - Mokaya, Jolynne
AU - Maponga, Tongai G.
AU - Kramvis, Anna
AU - Dusheiko, Geoffrey
AU - Irving, William
AU - Delphin, Marion
AU - Said Mohammed, Khadija
AU - Downs, Louise O.
AU - Waddilove, Elizabeth
AU - Anderson, Motswedi
AU - Iwuji, Collins
AU - Msomi, Nokukhanya
AU - Ocama, Ponsiano
AU - Hamid, Saeed
AU - Adda, Danjuma
AU - Halford, Rachel
AU - Kabagambe, Kenneth
AU - Benschop, Kimberley S.M.
AU - Inzaule, Seth
AU - Chan, Polin
AU - Paul, Margaret Alia Samson
AU - Izumi, Kiyohiko
AU - Nisa, Tiara
AU - De Dieu Iragena, Jean
AU - Girón-Callejas, Amalia
AU - Kpossou, Aboudou Raïmi
AU - Jamiyu, Ganiyu
AU - Emmanuel, Omolara
AU - Balkissa, Mahamadou
AU - Keita, Mamadou
AU - Prabdial-Sing, Nishi
AU - Martinez, Alexander
AU - Magongo, Eleanor Namusoke
AU - Shao, Yiming
AU - Sued, Omar
AU - Sereno, Leandro Soares
AU - Shafer, Robert W.
AU - Lesi, Olufunmilayo
AU - Faini, Diana
AU - Easterbrook, Philippa
AU - Duncombe, Chris
AU - Jordan, Michael R.
AU - Matthews, Philippa C.
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/8
Y1 - 2025/8
N2 - In this Review, we summarise outputs from a multidisciplinary consultation convened by WHO between July 11 and 13, 2023, to discuss hepatitis B virus (HBV) drug resistance (HBVDR). Treatment of chronic HBV infection with highly effective nucleos(t)ide analogue agents, tenofovir and entecavir, is a crucial intervention that supports the global goal of elimination of HBV infection as a public health threat. The risk of HBVDR as a threat to treatment outcomes is currently considered low from a public health perspective; however, drug resistance can influence individual outcomes, particularly among those who are treatment-experienced. We highlight the need to develop appropriate prevention, monitoring, and surveillance approaches for HBVDR, to support investment in the global scale-up of HBV diagnosis and treatment. Recommendations for the HBVDR field will ultimately be incorporated into a WHO integrated Global Action Plan for drug-resistant HIV, viral hepatitis, and priority sexually transmitted infections.
AB - In this Review, we summarise outputs from a multidisciplinary consultation convened by WHO between July 11 and 13, 2023, to discuss hepatitis B virus (HBV) drug resistance (HBVDR). Treatment of chronic HBV infection with highly effective nucleos(t)ide analogue agents, tenofovir and entecavir, is a crucial intervention that supports the global goal of elimination of HBV infection as a public health threat. The risk of HBVDR as a threat to treatment outcomes is currently considered low from a public health perspective; however, drug resistance can influence individual outcomes, particularly among those who are treatment-experienced. We highlight the need to develop appropriate prevention, monitoring, and surveillance approaches for HBVDR, to support investment in the global scale-up of HBV diagnosis and treatment. Recommendations for the HBVDR field will ultimately be incorporated into a WHO integrated Global Action Plan for drug-resistant HIV, viral hepatitis, and priority sexually transmitted infections.
UR - https://www.scopus.com/pages/publications/105002323019
U2 - 10.1016/j.lanmic.2025.101076
DO - 10.1016/j.lanmic.2025.101076
M3 - Review article
AN - SCOPUS:105002323019
SN - 2666-5247
VL - 6
JO - The Lancet Microbe
JF - The Lancet Microbe
IS - 8
M1 - 101076
ER -
